Related Experiment Videos
Physical dependence produced by dihydroetorphine in mice
S Tokuyama1, F Nakamura, M Takahashi
1Department of Pharmacology, Faculty of Pharmaceutical Sciences, Nagasaki University, Japan.
Biological & Pharmaceutical Bulletin
|August 1, 1994
Summary
Dihydroetorphine (DHE) shows minimal physical dependence in mice, unlike morphine. DHE effectively suppresses withdrawal signs, suggesting potential as a safer clinical analgesic.
Area of Science:
- Pharmacology
- Neuroscience
- Drug Development
Background:
- Morphine is a potent analgesic but carries a significant risk of physical dependence.
- Understanding the dependence liability of novel analgesics is crucial for clinical safety.
Purpose of the Study:
- To compare the physical dependence potential of dihydroetorphine (DHE) with morphine in a mouse model.
- To investigate the relationship between DHE's antinociceptive duration and dependence development.
- To evaluate DHE's efficacy as a potential substitute for morphine in managing withdrawal symptoms.
Main Methods:
- Mice were administered dihydroetorphine (DHE) via intraperitoneal (i.p.) or intracerebroventricular (i.c.v.) routes using various schedules.
- Physical dependence was assessed by observing naloxone-precipitated withdrawal signs.
- DHE's ability to suppress morphine withdrawal signs was evaluated in a single dose suppression test.
Main Results:
- Daily administration of DHE for 6 days did not induce physical dependence.
- Repeated DHE injections at short intervals (1-2 hours) induced transient physical dependence, resolving within 2 hours.
- A single dose of DHE effectively suppressed morphine withdrawal signs without significant adverse effects, indicating its suitability as a morphine substitute.
Conclusions:
- Dihydroetorphine (DHE) exhibits a significantly lower physical dependence potential compared to morphine.
- The development of DHE-induced dependence is linked to the duration of its antinociceptive effect, which appears to be short-lived.
- DHE's potent antinociceptive effects coupled with minimal dependence liability suggest its potential for developing safer analgesics for clinical use.